'Do patients benefit in trials?' Talk by Prof. Jonathan Kimmelman, March 11th

The talk will introduce empirical evidence that questions the widespread assumption regarding the direct advantages patients gain through participating in clinical trials. It aims to assess whether potential benefits outweigh the burdens and the risks that individuals endure in support of drug development. Broader moral and policy ramifications that arise from these findings and concern drug regulation, ethical oversight, and innovation policies will be unfolded.